G1 Therapeutics, Inc. Forecasted to Post Q3 2024 Earnings of ($0.11) Per Share (NASDAQ:GTHX)

G1 Therapeutics, Inc. (NASDAQ:GTHX) – Analysts at Wedbush raised their Q3 2024 earnings per share estimates for shares of G1 Therapeutics in a report issued on Monday, June 24th. Wedbush analyst D. Nierengarten now expects that the company will post earnings of ($0.11) per share for the quarter, up from their prior forecast of ($0.14). Wedbush has a “Outperform” rating and a $3.00 price objective on the stock. The consensus estimate for G1 Therapeutics’ current full-year earnings is ($0.53) per share. Wedbush also issued estimates for G1 Therapeutics’ Q4 2024 earnings at ($0.06) EPS, FY2024 earnings at ($0.55) EPS, Q1 2025 earnings at ($0.05) EPS, Q2 2025 earnings at ($0.05) EPS, Q3 2025 earnings at ($0.03) EPS, Q4 2025 earnings at ($0.03) EPS, FY2025 earnings at ($0.16) EPS, FY2026 earnings at ($0.06) EPS and FY2027 earnings at $0.14 EPS.

A number of other research analysts have also weighed in on GTHX. HC Wainwright cut their price objective on G1 Therapeutics from $9.00 to $3.00 and set a “buy” rating on the stock in a report on Tuesday. Needham & Company LLC lowered their price target on G1 Therapeutics from $12.00 to $6.00 and set a “buy” rating on the stock in a research report on Tuesday.

G1 Therapeutics Price Performance

Shares of NASDAQ GTHX opened at $2.25 on Thursday. The business has a fifty day moving average price of $3.71 and a 200 day moving average price of $3.59. G1 Therapeutics has a 1-year low of $1.08 and a 1-year high of $6.14. The company has a debt-to-equity ratio of 1.34, a quick ratio of 2.55 and a current ratio of 2.94.

G1 Therapeutics (NASDAQ:GTHX) last posted its quarterly earnings data on Wednesday, May 1st. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). G1 Therapeutics had a negative net margin of 36.40% and a negative return on equity of 74.75%. The business had revenue of $14.48 million for the quarter, compared to analysts’ expectations of $15.21 million. During the same quarter in the previous year, the firm earned ($0.53) EPS.

Institutional Trading of G1 Therapeutics

A number of institutional investors have recently bought and sold shares of the business. Financial Advocates Investment Management acquired a new position in G1 Therapeutics in the 4th quarter valued at about $39,000. SG Americas Securities LLC purchased a new stake in G1 Therapeutics in the 1st quarter valued at approximately $58,000. Creative Financial Designs Inc. ADV lifted its stake in G1 Therapeutics by 98.1% in the 4th quarter. Creative Financial Designs Inc. ADV now owns 35,280 shares of the company’s stock valued at $108,000 after buying an additional 17,475 shares in the last quarter. Capstone Investment Advisors LLC purchased a new position in shares of G1 Therapeutics during the 4th quarter worth $76,000. Finally, Jump Financial LLC purchased a new position in shares of G1 Therapeutics during the 4th quarter worth $105,000. 24.21% of the stock is owned by hedge funds and other institutional investors.

G1 Therapeutics Company Profile

G1 Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.